| Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed A Walia, J Tuia, V Prasad Nature Reviews Clinical Oncology 20 (12), 885-895, 2023 | 27 | 2023 |
| Association between US drug price and measures of efficacy for oncology drugs approved by the US Food and Drug Administration from 2015 to 2020 MD Miljković, JE Tuia, T Olivier, A Haslam, V Prasad JAMA internal medicine 182 (12), 1319-1320, 2022 | 25 | 2022 |
| The promise and pitfalls of using crowdsourcing in research prioritization for back pain: cross-sectional surveys MA Bartek, AR Truitt, S Widmer-Rodriguez, J Tuia, ZA Bauer, ... Journal of medical Internet research 19 (10), e341, 2017 | 17 | 2017 |
| Eligibility for human leukocyte antigen–based therapeutics by race and ethnicity T Olivier, A Haslam, J Tuia, V Prasad JAMA Network Open 6 (10), e2338612-e2338612, 2023 | 15 | 2023 |
| Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers A Haslam, T Olivier, J Tuia, V Prasad BMC cancer 23 (1), 46, 2023 | 15 | 2023 |
| Systematic review and meta-analysis of randomized trials testing interventions to reduce physician burnout A Haslam, J Tuia, SL Miller, V Prasad The American journal of medicine 137 (3), 249-257. e1, 2024 | 14 | 2024 |
| Cancer drug price and novelty in mechanism of action MD Miljković, J Tuia, T Olivier, A Haslam, V Prasad JAMA Network Open 6 (12), e2347006-e2347006, 2023 | 9 | 2023 |
| Cost of drug wastage from dose modification and discontinuation of oral anticancer drugs M Lam, T Olivier, A Haslam, J Tuia, V Prasad JAMA oncology 9 (9), 1238-1244, 2023 | 7 | 2023 |
| A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target A Haslam, T Olivier, J Tuia, V Prasad European Journal of Cancer 178, 227-233, 2023 | 6 | 2023 |
| Profile of the oncology physician workforce and the characteristics of attrition J Tuia, A Haslam, V Prasad JCO oncology practice 19 (7), 465-472, 2023 | 5 | 2023 |
| Eventual success rate and predictors of success for oncology drugs tested in phase I trials A Haslam, T Olivier, K Powell, J Tuia, V Prasad International journal of cancer 152 (2), 276-282, 2023 | 3 | 2023 |
| Characteristics and outcomes of new molecular oncology drug approvals, in combination or monotherapy S Ranganathan, A Haslam, J Tuia, V Prasad Journal of Cancer Policy 39, 100462, 2024 | 2 | 2024 |
| Multiple myeloma: challenges with deciding the optimal sequencing strategy A Walia, A Haslam, J Tuia, V Prasad Frontiers in Pharmacology 14, 1231720, 2023 | 2 | 2023 |
| Frequency and characteristics of trials using medical writer support in high-impact oncology journals E Buck, A Haslam, J Tuia, V Prasad JAMA network open 6 (2), e2254405-e2254405, 2023 | 2 | 2023 |
| Measuring the effectiveness of public involvement in transportation planning and project development B Brown, K Gunby, J Strausz-Clark, A Frugé, S Glaze, M Findlay, J Tuia, ... NCHRP research report 2019 (905), 1-P2, 2019 | 2 | 2019 |
| Assessing patient burden and benefit: A decade of cabozantinib clinical trials GK Hughes, NB Sajjadi, B Gardner, JK Ramoin, J Tuia, A Haslam, ... International Journal of Cancer 154 (8), 1464-1473, 2024 | 1 | 2024 |
| Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review P Crotty, K Kari, GK Hughes, C Ladd, R McIntire, B Gardner, AM Peña, ... Targeted Oncology 19 (2), 161-173, 2024 | 1 | 2024 |
| Scoping review of published oncology meta-analyses in high-impact oncology journals A Haslam, J Tuia, V Prasad JAMA network open 6 (6), e2318877-e2318877, 2023 | 1 | 2023 |
| A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers V Prasad, A Haslam, J Tuia Journal of Cancer Policy 31, 100319, 2022 | 1 | 2022 |
| Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Abiraterone Clinical Trials M Rashid, E Oldham, GK Hughes, AM Peña, C Ladd, B Gardner, ... Journal of Urologic Oncology 22 (3), 211-223, 2024 | | 2024 |
